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Cancer constantly finds ways to survive, so we must find new ways to stop it. A major attribute of 
cancer cells is increased oxidative stress, occurring in the form of reactive oxygen species (ROS). 
Basal ROS generation commonly occurs in all types of cells and is essential for normal cellular 
growth and function. However, in contrast to its beneficial attributes when generated at low 
concentrations, excessive production of ROS is harmful to the cell. High levels of ROS can damage 
cellular function to the point of cell senescence or cell death. Certain cells are able to effectively adapt 
to increased ROS levels, activating endogenous antioxidant pathways as a way to survive the aberrant 
onslaught of oxidative stress. One antioxidant pathway that is often found to be upregulated in cancer 
cells is the thioredoxin pathway, and within the thioredoxin pathway exists a highly reactive 
selenocysteine-containing enzyme called thioredoxin reductase 1 (TrxR1). The observed 
overexpression of the antioxidant enzyme TrxR1 in cancer cells suggests that the enzyme serves as an 
integral combatant to increased oxidative stress levels, allowing cancer cells to survive and even thrive 
in the nocuous environment of elevated ROS.  
The studies comprising this thesis further examine the ability to inhibit TrxR1 function with small 
molecule drug candidates, the role such inhibition has on modulating ROS levels, and whether such 
inhibition is sufficient to elicit anticancer therapeutic effects.  
Paper I established a novel recombinant TrxR1 assay designed for high-throughput screening 
capabilities. The assay was designed to be dual-purpose, with the ability to detect TrxR1 substrate or 
inhibitory activity of the test compound within a single test sample. Using the library of 
pharmacologically active compounds (LOPAC1280), known substrates and inhibitors of TrxR1 in the 
library validated the assay.  Protoporphyrin IX (PpIX), a previously unknown inhibitor of TrxR1, was 
discovered to inhibit the enzyme in the screen. PpIX and two of its analogs displayed irreversible 
inhibition to the enzyme, with the capacity to inhibit cellular TrxR1 activity and inhibit cancer cell 
viability. The three porphyrin compounds illustrated how slight chemical modifications to the 
porphyrin ring core of PpIX could alter the inhibitory activity of TrxR1.  
Paper II examined various pharmacodymics and activities of the proteasome inhibitor b-AP15.  b-
AP15 was found to be rapidly taken up in cancer cells and quickly induce cell death irrespective of 
brief exposure times.  The reactive site of b-AP15 was determined to exist at the α,β-unsaturated 
carbonyl Michael acceptor moiety of the compound.  The half-life of b-AP15 in plasma was 
determined to be short, but coincided with the observed rapid uptake of the compound into cells.  In 
human hepatocytes, over 17 different metabolites were observed after compound treatment. b-AP15 
and many of its analogs, as opposed to bortezomib, were also found to be potent inhibitors of TrxR1.   
b-AP15 was also successfully able to inhibit TrxR1 in a cellular context. 
Paper III describes the effects of MJ25, a novel p53 transactivator and TrxR1 inhibitor, and 
Auranofin against malignant melanoma.  Both compounds were found to be effective inhibitors of 
malignant melanoma cell growth and viability. In redox profiling, both compounds irreversibly 
inhibited of TrxR1, displayed selenium compromised thioredoxin reductase-derived apoptotic protein 
(SecTRAP) activity, and caused increased cellular ROS production.   
Paper IV screened for novel TrxR1 inhibitors on a large scale and tested whether the newly 
discovered inhibitors would elicit anticancer effects. A structure activity relationship analysis of the 
two top TrxR1 inhibitors (TRi-1 and TRi-2) correlated enzyme inhibition to inhibition of cell viability. 
Both compounds exhibited potency across multiple cancer cell types in the NCI60 cell panel and 
individual cell line testing. Differential SecTRAP forming capabilities of the two compounds, 
compared with Auranofin, correlated a SecTRAP dependent cellular induction of H2O2 while lacking 
effects on mitochondrial function.  TRi-1 effectively inhibited tumor growth, decreased tumor 
metabolic activity, and was well tolerated in mouse models.  TRi-1 and Auranofin effectively 
inhibited tumor growth in syngenic mouse models.  
These studies reinforce the candidacy of TrxR1 as an anticancer drug target through the introduction 
of novel inhibitors of the enzyme displaying anticancer effects in vitro and in vivo, and through the 
exposition of anticancer drug candidates as inhibitors of the enzyme. 
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Though cancer is defined simply as a disease of uncontrolled cellular growth, the 
understanding of what cancer is and how it may be effectively treated is in constant 
evolution. Cancer is not a singular disease, but a series of diseases able to spur from any 
tissue type in the body, from various causal factors or random events. As conversation and 
study continues, cancers of every type continue to take a heavy toll.  In 2012 the World 
Health Organization (WHO) reported approximately 14 million new cases of the disease and 
over 8.2 million cancer-related deaths world wide 1.  
Because of its multifarious nature, treatment of cancer cannot logically occur from a single 
source, and Paul Ehrlich’s “magic bullet” concept to therapy cannot apply to this disease. To 
obtain efficacy against all forms, multiple therapies from multiple therapeutic venues are 
needed. Remarkably, the characterization of cancer has rapidly developed over the past 100 
years, leading to myriad clinical therapies ranging from surgery to radiation, to small 
molecule drugs, to immunotherapy. 
Of the many different types of therapies used to treat cancer, series of therapeutic treatments 
use small molecule drugs.  Small molecule drugs were first implemented as cancer therapies 
in the mid-twentieth century and were termed chemotherapeutics. Those introduced more 
recently are defined as targeted therapies. Chemotherapies are described as promiscuous, 
highly toxic drugs given at specific doses aimed at killing cancer cells without killing the 
patient. Targeted therapies, alternatively, are less toxic to healthy cells; they are classified as 
highly specific drugs that effect particular aberrations in cancer cells while harming fewer 
healthy cells. The main differences between these two distinctions of small molecule drugs 
are toxicity profiles, described mechanisms of action, and the era in which they were 
discovered. 
Like many scientific discoveries, the first anticancer chemotherapeutic resulted from an 
unlikely source. During WWII American researchers were secretly examining the physical 
effects and potential uses for novel chemical warfare agents. Nitrogen mustard, a small 
molecule derived from the chemical weapon mustard gas, was found to decrease the size of 
lymph nodes in rabbits in classified studies located in the laboratories of Yale University 2,3. 
The mustard gas derivative was then used to treat patients with lymphomas in 1942, laying 
the foundation for the many clinical trials to come 3,4. The nitrogen mustard 
chemotherapeutic, now known as mechlorethamine, is still available for clinical use today. 
Despite the success of nitrogen mustard, and the advent of other small molecule drug 
therapies in combating cancer, many people still terminally suffer from the disease and 
further improvements in therapy are greatly needed. 
A fundamental, if erratic, topic in cancer research is oxidative stress. Oxidative stress occurs 
when oxygen molecules become derivatized into reactive molecules, and antioxidants are not 
able to effectively inactivate or detoxify them. This leads to cell damage. Oxidative stress has 
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always been linked to cancer, though the understanding of its significance and roles in 
tumorigenesis, tumor progression, and use in therapy have been in constant flux. High levels 
of oxidative stress are known to damage DNA and other compartments of the cell, promoting 
carcinogenesis. Yet ironically, high levels of oxidative stress induced by chemotherapies or 
radiotherapies are viewed as a main mechanism of their therapeutic action. To complicate the 
matters further, the molecules associated with oxidative stress are essential for healthy 
cellular function, development, and survival. The variable nature of oxidative stress, between 
its sources and its utility, has made for a convoluted field of scientific study that has been 
making interesting advances since the turn of the twentieth century.  
The complexity of the role of oxidative stress in carcinogenesis and cancer therapies has led 
researchers to extensively examine the cellular mechanisms that combat oxidative stress in 
cancer, particularly antioxidant pathways. These pathways are often upregulated in cancer 
cells, acting as a compensatory mechanism to the high levels of oxidative stress. Activation 
of protective antioxidant pathways can enable cancer cells to survive and even thrive off of 
the typically deleterious increases in oxidative stress. The following chapters will describe the 
complexity of the relationship between reduction/oxidation (redox) biology, cancer, and 
cancer drug development, focusing on: major perspectives and understandings of cancer; 
reactive oxygen species (ROS); redox active antioxidant pathways and their role in cancer; 
and, thioredoxin reductase 1 and its implication as a drug target. 
1.1 CANCER 
1.1.1 Hallmarks of Cancer 
As Douglas Hanahan and Robert Weinberg have continued to describe since their seminal 
rendezvous at the top of a volcano, as knowledge expands, so does the need to acknowledge 
its great complexity 5. Their initial effort in characterizing cancer describes six general cancer 
traits, or hallmarks: resisting cell death, sustained proliferative signals, activating 
angiogenesis, enabling replicative immortality, evasion of growth suppressors, and activation 
of invasion and metastasis 6. These characteristics develop in a highly diverse fashion, with 
various causal and random forces driving tumorigenesis 7,8.  
In order to initiate tumorigenesis there must be a degree of genome instability, which 
generates a series of genetic mutations or aneuploidy. These genomic alterations result in 
activation of oncogenes, or the deletion or inactivation of tumor suppressor genes 9. 
Oncogenes like MYC 10 and RAS 11 become constitutively active upon mutation, driving 
cellular growth, dedifferentiation, and cell survival. Tumor suppressor genes like PTEN 12 
and e-cadherin 13 normally prevent tumors from forming, but their inactivation or deletion 
from the genome can result in tumorgenesis and aggressive tumor phenotypes. The tumor 
suppressor/oncogene p53, referred to as the “guardian of the genome,” 14 prevents 
tumorigenesis in its normal cellular function, loses that tumor-suppressing attribute upon 
deletion, and can even become oncogenic when specific mutations in the gene occur 15.  
Elucidation of Thioredoxin Reductase 1 as an Anticancer Drug Target 
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These few examples of genetic changes driving tumorigenesis highlight the vast diversity of 
the mechanistic basis in which tumors can be formed. Over a decade since the hallmarks of 
cancer were first establishment, at least eight or more general attributes have been added. 
While the driving forces behind the hallmarks were originally focused solely on genome 
instability, now tumor-promoting inflammation is also considered a driver of tumorigenesis 5.  
 
1.1.2  Non-Oncogenic Addictions and Synthetic Lethality 
In addition to genetic activation of oncogenes and the deactivation or deletion of tumor 
suppressor genes, cancer cells are understood to possess specific phenotypic traits resultant of 
their genetic malformations. These phenotypic adaptations have become known as non-
oncogenic addictions 16. Non-oncogenic addictions are characterized as stress phenotypes 
observed throughout cancers, which serve to support the growth and viability of cancer cells 
even though these cellular alterations themselves are not inherently tumorigenic. These 
phenotypes constitute an additional six traits on top of the initial six hallmarks of cancer: 
evading immune surveillance, metabolic stress, proteotoxic stress, mitotic stress, oxidative 
stress, and DNA damage stress (Fig. 1) 17.  
 
Figure 1.  Original Hallmarks of Cancer 6 with Cancer Cell Stress Phenotypes 17.  The original six hallmarks 
of cancer (top half of circle, solid color boxes) are combined with six stress phenotypes (bottom half of circle, 
white boxes).  The combination of oncogenic factors and suppression of cancer cell stress drives a tumorigenic 
state.  Reprinted from Publication Cell, 136 /5, Ji Luo,Nicole L. Solimini,Stephen J. Elledge, Principles of 
Cancer Therapy: Oncogene and Non-oncogene Addiction, 823-837, Copyright (2009), with permission from 
Elsevier.  
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Drug targeting non-oncogenic addictions may serve to sensitize cancer cells to alterations in 
the cellular environment independent of genotype, incorporating a concept known as 
“synthetic lethality” 18. Since non-oncogenic addictions are not the cause of tumorigenesis, 
but a resultant support mechanism for the tumors, inhibition or alteration should be 
deleterious only to the cancer cells that are heavily dependent upon its function for survival. 
Still, what constitutes a non-oncogenic addiction versus an oncogenic addiction is not always 
clear 17. One of the best examples of targeting a non-oncogenic addiction was performed with 
a compound named piperlongumine. Piperlongumine was found to selectively inhibit cancer 
cell growth via the induction of ROS, independent of P53 status 19. Though no specific target 
was identified, the phenotypic response was found to be highly specific to cancer cells. 
Another example of an ability to target non-oncogenic addictions is through DNA damage 
stress. Specifically targeting DNA repair mechanisms and inhibiting their function elicits 
DNA damage, resulting in cancer-specific cell death without observed toxic effects on 
healthy cells 20. Other examples of promising non-oncogenic addiction drug targets are heat 
shock protein 90 (HSP90), vascular endothelial growth factor 1 (VEGF1), mammalian target 
of rapamycin (mTOR), the proteasome, and various kinases 17.   
 
1.1.3  Warburg Effect and Metabolic Reprograming 
One prevailing characteristic that appears almost universally in cancer cells is the increased 
utilization of glucose for energy production. This phenomenon, which may fall into the 
definition of a non-oncogenic addiction, occurs even in the presence of oxygen and is called 
aerobic glycolysis 21. Normal, non-proliferating cells typically catabolize glucose and, in turn, 
generate the major currency of cellular energy, adenosine 5’-triphosphate (ATP). This normal 
process occurs via oxidative phosphorylation (OXPHOS) in the mitochondria. Otto Heinrich 
Warburg first observed that, in comparison to normal cells, tumor cells have a higher rate of 
glucose consumption paired with an in increased rate of lactate production 22. These 
observations indicated tumors produce most of their energy from glycolysis alone, and not 
through OXPHOS. Warburg additionally observed that it made little sense for the tumors to 
preferably utilize only glycolysis for energy production. In terms of quantity of ATP 
production, glycolysis can only produce four units of ATP per unit of glucose versus 36 units 
of ATP per unit of glucose when undergoing OXPHOS 23. Understanding what initially 
appeared to be a defect in cellular energy production in tumors, Warburg went on to 
hypothesize that the mitochondria in cancer cells were in fact damaged and dysfunctional 24. 
Despite the magnitude of Warburg’s initial discoveries regarding cancer cell metabolism, his 
extrapolated theories on mitochondrial dysfunction in cancer cells were unfortunately false 25-
27.  
Within the past twenty years, Warburg’s fundamental discovery of altered metabolism in 
cancer cells has resurged to the forefront of cancer research. An important aspect considered 
Elucidation of Thioredoxin Reductase 1 as an Anticancer Drug Target 
   
 
 5 
in Warburg’s observed shift in glucose utilization between normal and cancer cells is the 
differential energy demands of the two types of cells 28-34. The observation of this increase in 
non-ATP energy requirements and the observed changes in energy production and utilization 
in cancer cells has led to the concept of “metabolic reprogramming” 35. Highly proliferating 
cancer cells need large quantities of nicotinamide adenine dinucleotide phosphate (NADPH) 
in order to generate a biomass and sustain redox homeostasis in addition to production of 
ATP 33,34. Per molecule of glucose, biomass synthesis is rate-limited through NADPH levels, 
not ATP 23,33. Therefore, using a catalytic pathway that produces more NADPH per respective 
glucose molecule is more economical and efficient, even though the major energy source of 
the cell, ATP, is produced in lower quantities. Recent research has shown the mitochondria in 
cancer cells actually retain their functionality; however, their function appears to be diverted 
from OXPHOS to support biomass production and other macromolecule generation 36. 
 
1.2 REACTIVE OXYGEN SPECIES 
Integral components to cell metabolism and function, ROS are both part of normal cellular 
function as well as driving forces in disease 37. Derivatives of molecular oxygen (O2) 38, ROS 
are produced through various energy-generating and energy-consuming cellular processes. 
ROS can also occur from external sources like UV radiation 39, environmental pollutants 40, 
and toxic heavy metals 41. ROS are named as such because electrons prefer to be in the most 
grounded state possible within an atom, meaning O2 derivatives with one or more additional 
electrons want to “lose” them, and are reactive with other atoms or molecules 42. The 
reactivity of each type of ROS depends on whether the electrons are in a paired or unpaired 
state, and how that pairing occurs. Additionally, the cellular effect of each type of ROS is 
dependent upon a balance between the activity of each system responsible for the ROS 
generation and the specific pathways responding to such ROS generation 43. This balance is 
referred to as redox homeostasis 44. The extent to which cells produce ROS and activate 
respondent redox pathways can determine the difference between cell proliferation, activation 
of cell death, induction of cellular senescence, driving of tumorigenesis, and sustained tumor 
microenvironments 45,46. This section will review forms of ROS and how they are generated 
within the cell, and the role ROS plays in tumorigenesis and cancer therapy.   
 
1.2.1 Mitochondrial ROS 
The cellular formation of ROS can occur either passively, through the inefficiency of O2 
utilizing pathways, or actively, through the enzymatic conversion for specific functional 
processes (Fig.2). Through the production of ATP, the cell’s most abundant energy source, 
large quantities of superoxide (O2•-) are produced. This ROS generation occurs through the 
process of OXPHOS, where energy is passed through the electron transport chain (ETC) in  




Figure 2. Cellular Sources of ROS Production. Production of superoxide (O2•-) can derive from many 
different sources within the cell, including the mitochondria, cytosol, endoplasmic reticulum (ER), and 
peroxisomes. O2•- is quickly converted into hydrogen peroxide (H2O2) through catalytic or non-catalytic 
mechanisms. H2O2 can also be directly produced from oxygen (O2) through oxidation of Ero1 in the ER. In the 
presence of metals, H2O2 can be converted into the highly reactive hydroxyl radical (•OH). •OH are extremely 
short lived within the cell, instantaneously reacting with the molecules in their immediate vicinity. Black dots 
represent electrons in oxygen atoms, grey dots represent hydrogen electrons shared with oxygen atoms, and red 
dots represent free radicals (lone pair electrons) in certain oxygen atoms. Colors represent relative molecular 
reactivity, ranging from green (low reactivity) to red (high reactivity). 
the mitochondria 23,47,48. A series of four multi-subunit protein complexes located in the inner 
membrane space of the mitochondria, the ETC utilizes O2 and energy produced from 
glycolysis and the tricarboxylic acid cycle to produce ATP. In the final stage of OXPHOS, a 
four-step reduction of O2 occurs to generate water (H2O). This step is not 100 percent 
efficient, leading to the generation of a one electron reduced O2•-. After O2•- is generated, it 
can spontaneously convert from the radial molecule into the non-radical molecule hydrogen 
peroxide (H2O2), or it can be actively converted to H2O2 by super oxide dismutase (SOD) 49. 
H2O2 is still a reactive molecule capable of causing cell damage, albeit a less reactive form of 
ROS compared to O2•-. 
 
1.2.2 Endoplasmic Reticulum ROS 
The endoplasmic reticulum (ER) is known to have a unique redox environment. A reducing 
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protein structure like disulfide bonds. The ER is therefore in an oxidized state for such bonds 
to be able to form. This disulfide bond formation cannot occur just from an oxidizing 
environment, it has to be facilitated by protein disulfide isomerase (PDI), a protein with 
similarities to thioredoxins 50. In order to activate PDI to assist in protein disulfide formation, 
ER oxireductin (Ero1) has to react with O2, oxidizing the protein and producing H2O2 51. 
Oxidized Ero1 can then react with, and oxidize, PDI. Monooxygenases, a class of membrane 
bound proteins localized in the ER, include the metabolic P450 enzymes, and are also a 
significant source of O2•- under cellular stress 52. 
 
1.2.3 Peroxisome ROS 
Peroxisomes, like the mitochondria and ER, consume O2. One of the main functions of 
peroxisomes is the β-oxidation of fatty acids 53. H2O2 is the most common form of ROS found 
in the peroxisome, though O2•-, •OH, and •NO are generated in this sub compartment as well 53. 
Oxidizing enzymes in the peroxisome include Acyl-CoA oxidases, xanthine oxidase, 
pipecolic acid, and nitric oxide synthase (NOS) 53.   
 
1.2.4 Additional Endogenous Sources of ROS 
Another source of O2•- production is through NADPH oxidase activity. NADPH oxidases are 
membrane-associated proteins utilized for purposeful generation of ROS in lymphocytes and 
phagocytes as a mode of killing foreign organisms, infected cells, and dysfunctional cells 54. 
Metals like copper and iron can also be sources of ROS. Through Haber-Weiss and Fenton 
reactions (Fig.3), O2•- and H2O2 can produce highly reactive and unstable hydroxyl (•OH) 
radicals 55.   
 
Figure 3. Haber-Weiss and Fenton Reactions. The Haber-Weiss reaction is a two-step reaction where A) 
metals oxidize superoxide (O2•-) to form molecular oxygen (O2), then perform a Fenton reaction B) where metals 
reduce hydrogen peroxide (H2O2) to a hydroxyl (OH-) and a hydroxyl radical (•OH). 
These examples of ROS generating systems illustrate the innate and elaborate existence of 
cellular ROS production in normal cellular function. When these systems amplify in function 
or lose their regulatory mechanisms, they can give rise to carcinogenesis, aiding in cancer cell 
growth and development 38. 
A) Fe3+(Cu2+) + O2•-         Fe2+(Cu+) + O2     
 
 
B) Fe2+(Cu+)  + H2O2        Fe3+(Cu2+)  + OH- + •OH     
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1.3 REDOX ACTIVE AND ANTIOXIDANT PATHWAYS  
The glutathione (GSH) and thioredoxin (Trx) pathways are the two major redox-signaling 
and antioxidant pathways within cells. Both pathways are involved in myriad of cellular 
processes including cell proliferation, apoptosis, detoxification, antioxidant activity, and 
sustaining cellular redox homeostasis 56. The GSH and Trx pathways have convergent and 
divergent mechanisms of action, creating a dynamic functional relationship that is still being 
elucidated today. A clear example of how these two pathways co-function is the reduction of 
ribonucleotide reductase (RNR), the enzyme responsible for generating deoxyribonucleotides 
needed for deoxyribonucleic acid (DNA) synthesis 57,58. Various activities of both the GSH 
and Trx pathways have been linked to enabling factors of cancer cell growth and survival 59,60. 
This section will give an overview of the major components of the GSH and Trx systems and 
their observed roles in cancer.  
 
1.3.1 Glutathione 
The predominant component of the glutathione pathway is γ-L-glutamyl-L-cysteinylglycine, 
or better known as glutathione (GSH), a 307 dalton tripeptide consisting of glutamate (Glu), 
cysteine (Cys), and glycine (Gly) 61. GSH is the most abundant signaling peptide found 
intracellularly, ranging between 0.5-10mM within all types of mammalian cells 62,61. GSH is 
also found extracellularly, and is produced through efflux from liver cells into the plasma 63. 
GSH can exist in two forms, a reduced GSH monothiol and an oxidized (GSSG) pair of two 
GSH molecules joined through a disulfide bond. The major form of the tripeptide in 
mammalian cells, over 95%, is the reduced form 64. Reduction of GSSG is facilitated through 
the NADPH-dependent, homodimeric flavin adenine dinucleotide (FAD) containing enzyme 
glutathione reductase (GR) 65 or through de novo synthesis of GSH. Synthesis of GSH occurs, 
first, through formation of γ-glutamylcysteine from Glu and Cys via glutamate cysteine 
ligase; and secondly, through formation of GSH from γ-glutamylcysteine and glycine via 
GSH synthetase 61. When cellular levels of Cys are depleted and GR is absent, alternative de 
novo synthesis of GSH can occur through generation of Cys through cystathionine γ-lyase 
trans-sulfuration of methionine (Met) 66. GSH activates and interacts with other components 
of the GSH pathway, contributing to cellular functions such as DNA synthesis, xenobiotic 
detoxification, cell signaling, and antioxidant defense 62.  
 
1.3.2 Glutathione Peroxidase 
Gluthione Peroxidase (GPx) proteins catalyze a GSH-dependent removal of multiple types of 
hydroperoxides from cells 67. Gpxs react with various peroxides resulting in the generation of 
byproducts such as H2O and alcohol. Such active depletion of ROS serves as a cellular 
mechanism to prevent ROS-induced cellular damage 68. In humans, forms GPx 1-8 have been 
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discovered. GPx4 is a unique GPx in that it is the only GPx known to able to directly reduce 
lipid hydroperoxides 69. The active site in GPxs is a tetrad in most isoforms, and facilitates the 
recruitment of GSH to the redox active moiety 70. Human GPx1-4 and GPx6 all contain a rare 
selenocysteine (Sec) amino acid in their active site 71. The Sec amino acid located within 
GPx1-4 and GPx6 is embedded into a pocket located near the surface of the protein 72. 
 
1.3.3 Glutaredoxin 
Glutaredoxins (Grxs) are oxidoreductase proteins that are primarily reduced in a two-step 
reaction by GSH, and were first recognized for their ability to donate electrons to RNR 73. 
There are two main types of Grxs, ones that contain a dithiol Cys-Pro-Tyr-Cys active site, 
and ones that contain a monothiol Cys-Gly-Phe-Ser active site 74. Grxs share a large degree of 
structural and functional homology to Trxs, e.g. RNR 73 reduction and direct inhibition of 
apoptosis signal-regulating kinase (ASK1) 75. Grxs also possess additional functionalities 
compared to Trx like catalyzing S-glutathionylation and deglutathionylation 76. Examples of 
crosstalk between the GSH and Trx pathways have been observed in mammalian-based 
studies, with human Grxs shown to reduce thioredoxin 1 (Trx1) and peroxiredoxins (Prxs) 
77,78. 
 
1.3.4 Glutathione S-Transferase 
There are three major forms of glutathione S-transferases (GSTs), cytosolic, mitochondrial, 
and microsomal, all initially named for their cellular localization and ability to catalyze the 
reaction of GSH to various molecules containing electrophilic moieties 79. GST catalyzed 
glutathionylation is the main cellular mechanism responsible for metabolism and 
detoxification of various xenobiotics, though GSTs can also perform additional functions like 
steroid, leukotriene, and prostaglandin synthesis 80,81. In some special cases a GST can serve 
as a lipid hydroperoxidase 82. Nomenclature of the GSTs falls in to seven categories, alpha, 
mu, pi, theta, zeta, omega, and sigma, based on their amino acid sequence, or gene families 83. 
The cytosolic and mitochondrial GSTs are soluble, whereas the microsomal GSTs are 
membrane associated proteins and have been redefined as membrane-associated proteins in 
eicosanoid and glutathione (MAPEG) metabolism 84.  
 
1.3.5 Thioredoxin 
Trx is the central enzyme within the Trx pathway. It was first identified as an electron donor 
for DNA synthesis 85, and is activated by the NADPH-dependent, selenocysteine containing 
flavoenzyme thioredoxin reductase (discussed in Chapters 4 and 5) 86. There are three main 
forms of Trx found in humans, cytosolic (Trx1), mitochondria (Trx2), and spermatozoa 
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(SpTrx). Trx1 is additionally found in the nucleus 87, as well as extracellularly along with a 
truncated form of the enzyme, Trx80 88. Trxs are structurally characterized by a distinctive 
Trx fold containing a N-terminal βαβ and C-terminal ββα motifs 89. The Trx fold is not 
limited to Trxs as it is seen in other cysteine-reactive redox enzymes like Grxs, GPxs, GSTs, 
and DsbA; however, aside from sharing a broad structural association, the other Trx fold-
containing proteins possess different redox activities and have large sequence diversity 89. 
Human Trx activity is dependent on a conserved disulfide motif, Cys-Gly-Pro-Cys 90. In 
addition to activation of Trx through TrxR1 activity, studies have shown that Trx1 can be 
reduced through the GSH pathway 77. Trx’s functional abilities have been connected to the 
activation of a variety of proteins within the cells, including RNR 58, p53 91, Prxs, protein 
tyrosine phosphatases 92, phosphatase and tensin homolog (PTEN) 93, and MSR. Trx has also 
been shown to inactivate proteins like ASK1 94.  
 
1.3.6 Peroxiredoxin 
Prxs are the functional analogs to GPxs in the Trx pathway. Prxs possess the ability to reduce 
H2O2, lipid hydroperoxides and peroxynitrite, and are activated through Trx reduction 95. 
There are six different Prxs found in humans, Prx1-6. Prx1-4 are 2-Cys typical Prxs, having a 
redox cycling mechanism consisting of an intermolecular disulfide reduction and reformation 
of the head-to-tail homodimer upon oxidation 96. Prx1 and Prx2 are found mainly within the 
cytosol, Prx3 is located in the mitochondria, and Prx4 is located in the endoplasmic 
reticulum. Prx5 is considered an atypical Prx because instead of normally forming a 
homodimer in its oxidized state, the protein more often forms an intramolecular disulfide 
bond, remaining in the monomeric form 97. Prx5 has been found in the cytosol, the 
mitochondria, and peroxisomes 95. Prx6 is a 1-Cys Prx and yet another example of crosstalk 
between the GSH and Trx pathways. Prx6 is reduced by GSH-reduced GSTp and not Trx1 98. 
  
1.3.7 Redox Pathways in Cancer 
The role of the GSH and Trx pathways in cancer is robust, being there direct and indirect 
examples of each pathway supporting cancer cell growth, survival, and function. Since the 
1980’s, research on redox pathways and their role in cancer has grown exponentially (Fig. 4).  
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Figure 4. The amount of papers published on “Redox” and “Redox and Cancer” in PubMed from 1930 to 
current day. 
The resilient nature of the GSH and Trx pathways can transform the normally protective 
mechanisms against oxidative stress to survival mechanisms against a cancer cell’s aberrant 
ROS production. It is important that in this transformation from “helpful to hurtful” in a 
living organism, both GSH and Trx pathways are considered together. Harris et. al. 2015 
showed that GSH serves as a protective mechanism to cancer, increasing the time of tumor 
free survival in mice with normal GSH production compared to mice with genetically 
impaired GSH synthesis pathways 99. Harris et. al. 2015 went on to show that once tumors 
onset, inhibition of GSH levels had no effect on tumor growth and that inhibition of the Trx 
pathway was then necessary for tumor growth inhibition 99. 
The cancer supporting antioxidant activities of the GSH and Trx pathways can be 
extrapolated through the observed upregulation of various components in each pathway. GRs 
and GPxs have been found to be upregulated in human lung cancer tissues 100. Higher GPx 
levels in cancers could help to combat the increased H2O2 levels found in cancer. Similar to 
GPxs, Prxs were also found to be upregulated in lung cancer 101 and thyroid cancer 102, 
suggesting further potential to contribute to the scavenging of excessive ROS production.  
Activity and expression levels of GSTs have been found to be increased in lung cancer, colon 
cancer, head and neck cancer, stomach cancer, and eshophageal cancer 103,104. Cancer cells 
overexpressing GSTs are highly correlated to drug resistance and, if not directly impeding 
drug efficacy, the increased GST levels have also been connected to the prevention of cancer 
cell death through indirect inhibition of ASK1 105,106. Other components of the antioxidant 
pathways able to impede on ASK1 function are Grx 75 and Trx1 94.  Trx1 overexpression has 
also been observed in lung cancer and liver cancer 101,107,108. 
The hyperactivation of the GSH and Trx pathways and the evolution of their protective 
functions to the benefit of cancer cells support the notion of redox active antioxidant 
pathways serving as non-oncogenic addictions. Increased activity of these two pathways is 
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and dysfunctional metabolic functions. As a non-oncogenic addiction, the GSH and Trx 
pathways coalesce their individual activities to change the entire cellular redox homeostasis 
and tolerance to oxidative stress. Completely abolishing the activity of the two pathways 
would prove wholly toxic because of the essential functions they both possess. However, 
inhibiting one or multiple components of the GSH or Trx pathway may serve therapeutic 
benefit against cancer, potentially impeding upon drug metabolism, suppressing activated 
proliferation, or effectively decreasing the high tolerance to oxidative stress in cancer cells 
(Fig. 5) 109.  
 
Figure 5. Cancer Cell Redox Biology. Trachootham et al. 2009 describe the differences in ROS production and 
the antioxidant response between normal and cancer cells. Normal cells have basal levels of ROS production as 
well as antioxidant activity. When moderate increases in oxidative stress occurs in normal cells, increasing ROS 
levels, the cells are able to survive through activation of antioxidant pathways, e.g. the GSH and Trx pathways. 
If the levels of ROS become too high, a normal cell will not be able to activate sufficient antioxidant activity to 
counteract the additional ROS, causing cell death. Cancer cells have increased basal oxidative stress levels 
compared to normal cells, paired with an increased amount of antioxidant activity. The increased antioxidant 
activity of cancer cells allows for the cell to survive levels of ROS that would typically cause cell death in a 
normal cell. Activated antioxidant activity in cancer cells helps the cells to survive, and it also creates a potential 
vulnerability to oxidative stress modulation. Slight increases to the already highly levels of ROS in a cancer cell 
may be sufficient to induce cell death. Alternatively, suppression of the increased antioxidant activities of cancer 
cells may sensitize the cells to their high oxidative stress environment and cause cell death. Reprinted by 
permission from Macmillan Publishers Ltd: NATURE REVIEWS DRUG DISCOVERY (Trachootham et al. 
2009), copyright (2009). 
 
1.4 THIOREDOXIN REDUCTASE 1 
Thioredoxin reductase (TrxR) proteins are members of the pyridine nucleotide disulfide 
oxidoreductase family 110. Different from most proteins, TrxR’s contain an additional amino 
acid to the common 20 amino acids found in proteins of all organisms. This amino acid is 
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called selenocysteine (Sec), and has been coined the 21st amino acid 111. There are three types 
of TrxR’s found in mammalian cells, all containing a Sec residue. They are cytosolic 
thioredoxin reductase 1 (TrxR1), mitochondrial thioredoxin reductase 2 (TrxR2), and testis 
specific thioredoxin glutathione reductase (TGR) 112-114. Utilizing Sec in the main active site 
of the enzyme, TrxR’s are highly reactive proteins that function as catalysts for the Trx 
pathway 115. TrxR1 is the most abundant enzyme of the three proteins, supporting multiple 
cellular signaling processes and directly performing antioxidant activities 115. With its major 
roles in cell function and redox homeostasis, TrxR1 has been proposed to be a target for 
anticancer therapies 59,94,116,117. This section will focus on TrxR1, examining the unique 
machinery required for its synthesis, the structural and functional aspects of the enzyme, and 
its known substrates and inhibitors. 
 
1.4.1  Selenocysteine and Selenoprotein Synthesis 
The Sec amino acid is much like Cys in terms of structure and function. Sec differs from Cys 
by only one atom, with a selenium atom in place of the sulfur atom in the radical group of the 
amino acid (Fig. 6). Selenium and sulfur are also quite similar, atomically speaking. They are 
both characterized as other non-metals, have the same oxidation states, and posses the same 
number of valence electrons. However, there are differences in the activation energies 
between selenium and sulfur, most likely due to the fundaments of molecular orbital theory. 
Sec is a stronger acid and more reactive compared to Cys, with Sec having an acid 
dissociation constant (pKa)=5.2, and Cys having a pKa=8.3 118. Sec additionally has a much 
lower redox potential of  -488mV compared to Cys having a redox potential of -233mV 119. 
The structural similarities and energetic differences between the two amino acids, and the 
incorporation of an additional amino acid into the proteome have established a higher order 
of complexity in protein expression and function. 
 
Figure 6. Chemical structures of selenocysteine and cysteine. 
Selenoproteins were first identified through the discovery of GPx back in 1973 120. At a 
surprise to researchers who discovered the protein, full length GPx was expressed in 
mammalian cells although GPx has a TGA stop codon within the open reading frame of the 
!"#"$%&'()"*$"+,!"&-+ .'()"*$"+,.'(-+
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DNA sequence 121. Sec-proteins are found primarily within multicellular animals, and in some 
cases in archaea and bacteria 122,123. Despite the knowledge of selenoproteins existing in many 
organisms, selenoproteins went largely ignored and were not incorporated into the analysis of 
the human genome project 124. Through the utilization of another characteristic of 
selenoprotein synthesis, the selenocysteine insertion sequence (SECIS) element, it was later 
discovered that there are a total of 25 selenoproteins in the human proteome 125. 
The insertion of Sec into proteins requires additional and highly complex translational 
machinery relative to normal protein synthesis 126. Firstly, selenocysteine does not occur 
naturally and must be synthesized within the cell. This begins with conversion of selenite, a 
naturally occurring trace element, into selenophosphate via selenophosphate synthetase 
(SPS2). Using seryl-tRNA synthetase and serine-tRNA to create phosphoserine-tRNA, 
selenocysteine synthase (SLA) then utilizes the selenophosphate to convert the phosphoseryl-
tRNA into a selenocysteyl-tRNA (Sec-tRNA) 127. The Sec-tRNA will then recognize a UGA 
stop codon with the assistance of more co-translational machinery for Sec insertion into the 
protein sequence. Normally, a UGA stop codon will provoke cessation of protein translation. 
The SECIS element, located at the 3’ untranslated region (UTR) of a selenoprotein’s mRNA, 
allows cofactor binding and subsequent suppression of translation termination 128. This stem-
loop structure can be comprised of various nucleotides, but must have a conserved secondary 
structure of two helices with an internal loop structure placed in between 129. The unique 
structure of the SECIS element enables the SECIS binding protein (SBP2) 130 to interact with 
the eukaryotic selenocysteine-specific elongation factor (eEFsec) 131 and recruit the Sec-
tRNA to the ribosome-bound mRNA, thus allowing for the insertion of the Sec amino acid 
into the protein sequence.   
 
1.4.2  Structure and Activation 
The major species of mammalian thioredoxin reductase 1 (TrxR1) exists as a homodimer 
configured in a head-to-tail orientation, with each subunit roughly weighing 55kDa. TrxR1 
can additionally exist as a homotetramer or a high oligomer, though it is much less common 
and much less reactive relative to the dimeric form 132. There are five different splice variants 
of TrxR1 found within cells 133. Located at a the penultimate residue in the protein sequence 
in TrxR1, the Sec amino acid forms a selenothiol bond with a neighboring Cys and serves as 
the main catalytic residue when the enzyme is reduced 113,134. The process of reducing TrxR1 
occurs through an electron flow from the N-terminus of one subunit in the dimer to the C-
terminus of the other subunit (Fig. 8A). This begins with NADPH binding to one of the dimer 
subunits and transferring electrons to the FAD. The electrons from the FADH2 are then 
transferred to a dithiol motif in the N-terminus of the same TrxR1 subunit. This reduced 
moiety then reduces the selenothiol motif in the C-terminus of the other subunit within the 
dimer, fully activating the enzyme complex for catalysis 135.  
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TrxR1 has a multitude of functions in a cellular context, acting as a highly reactive redox 
protein and a direct antioxidant protein 86,115. The effects and signaling events spurred from 
TrxR1’s activity are widespread, as can be understood from the highly diverse substrates of 
the enzyme. TrxR1 has been reported to directly interact with proteins, lipids, and a variety of 
small molecules. Cytosolic protein Trx1 is recognized as the principle substrate of TrxR1, 
and is also the most characterized 56. Trx1 activity is highly diverse, interacting with and 
affecting a wide range of cellular processes both intra- and extracellularly (described above). 
Other proteins known to be reduced by TrxR1 include PDI 136, Grx2 137, and thioredoxin 
related protein 14kDa (Trp14) 138.  
Although the cellular significance is not known for all of its substrate interactions, TrxR1 is 
also known to reduce various small molecules. An array of different quinones like 5,5′-
dithiobis-(2-nitrobenzoic acid) (DTNB) and 5-hydroxy-1,4-naphthalenedione (juglone) are 
substrates of TrxR1 139,140. Selenium containing small molecules like selenite 141, 
selenoglutathione 142, selenocysteine 134, and ebselen 143 can be reduced by TrxR1 as well. 
Other substrates of TrxR1 include H2O2 134 and lipid hydroperoxides 144, lipoic acid and 
lipoamide 145, dehydroascorbate (oxidized vitamin C) 146, menadione (vitamin K) 139, and 
alloxan 147.   
The substrates described here having known cellular functions, connect TrxR1 substrate 
activities to cell growth and proliferation, protein folding, apoptosis signaling, and direct 
antioxidant activity. Due to the complex network of activity that is formed with TrxR1 
function, it is likely that many more substrates and subsequent cellular functions of the 
enzyme have still yet to be elucidated.   
 
1.4.4  Inhibitors  
The nucleophilic nature of reduced TrxR1 renders it a highly reactive enzyme 113,134. Due to 
this nucleophilicity, a cornucopia of compounds with varying degrees of electrophilicity have 
been shown to inhibit TrxR1 148-151. To begin from a historical chemotherapeutic point of 
view, interestingly, mustard gas derivatives carmustine, chlorambucil, and melphalan, as well 
as other experimental mustard derivatives, are effective inhibitors of TrxR1 in recombinantly 
expressed enzyme, cellular, and clinical settings 152-154. Because of the highly reactive nature 
of TrxR1, it is not surprising that alkylating agents react with TrxR1. An important detail of 
TrxR1 inhibitors is that, depending on their reactivity, they can potentially interact with other 
cellular components. Utilizing the progeny of nitrogen mustard as an example for this 
potential promiscuity, unlike chlorambucil and melphanan, carmustine is additionally a 
potent inhibitor of GR 153.  
William C. Stafford 
 
16 
A group of compounds that are often described to inhibit TrxR1 are transition metal-
containing compounds. Transition-metal containing compounds, in their ability to become 
protonated 155, become prime candidates in reacting with the reduced form of TrxR1. 
Cisplatin, along with many other platinum-based compounds, is an effective TrxR1 inhibitor 
and inhibitor of cancer cell growth 153,156-162. However, cancer cells often become resistant to 
cisplatin treatment, and cisplatin resistant cells have been shown to have increased Trx1 and 
TrxR1 levels 163,164. Some of the most potent transition metal-containing TrxR1 inhibitors, and 
forefront anticancer drug candidates as TrxR1 inhibitors, are gold compounds 165-173. The 
extensive research on gold-containing compounds as TrxR1 inhibitors for the use as 
anticancer therapies derives from the anti-rheumatic and FDA approved drug Auranofin. 
Auranofin is moderately well tolerated in humans, is an effective TrxR1 inhibitor, and is 
currently in multiple clinical trials for cancer treatment 174. Moreover, Auranofin has been 
shown to successfully inhibit cisplatin resistant cancer cell growth 164. Other compounds 
containing transition metals like palladium 175, mercury 176-180, silver 181, gadolinium 182, 
ruthenium 183-185, and chromium 186 have also been shown to inhibit TrxR1. Reactivity of 
transition metal-containing compounds with TrxR1 is not always exclusive, however.  
Studies with gold and platinum phosphine compounds have shown these compounds inhibit 
GR in addition to TrxR1 187.  
Another group of compounds, naturally occurring compounds, are known to inhibit TrxR1. 
The group of naturally occurring inhibitors of TrxR1 is diverse, and the small molecule 
inhibitors of the enzyme derive from multiple sources in nature. Two compounds found in 
red wine, vegetables, fruits, and nuts that effectively inhibit TrxR1 are the polyphenolic 
compounds myricetin and quercetin 188. Remarkably, various types of red wines as a whole 
effectively inhibit TrxR1 in cell culture models 189. Epigallocatechin gallate and its derivatives 
are popular polyphenolic compounds found in green tea, and are effective TrxR1 inhibitors 
with proposed anticancer effects 190. The TrxR1 inhibitor curcumin, yet another phenolic 
compound, is found within turmeric and has been suggested to have anticancer potential 191 
192,193. Sulforaphane, an isothiocyanate as opposed to a flavonoid or polyphenol, is found in 
cruciferous vegetables like broccoli, Brussels sprouts, and cabbages, has been shown to 
inhibit TrxR1 in recombinant enzyme and cellular settings, and too has been suggested to 
possess anticancer effects 194. Other isothiocynates are also known to inhibit TrxR1 194. The 
small molecule responsible for the smell and flavor in cinnamon, cinnamaldehyde, inhibits 
TrxR1 activity in enzymatic and cellular settings without affecting GR activity 195. Naturally 
occurring TrxR1 inhibitors are not only found in plants, fruits, and nuts.  Studies have shown 
functional lipids like prostaglandins and byproducts of lipid peroxidation like 4-hydroxy-2-
nonenal, produced in the human body, are also inhibitors of TrxR1 196-198. 
A subgroup of naturally occurring compounds that inhibit TrxR1 fall within the functional 
realm of quinones 199. Different types of quinone compounds have been described to inhibit 
TrxR1 in both enzymatic and cellular experiments, and some have shown efficacy within in 
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vivo models 200-203. Quinones are a diverse, pKa-dynamic group of compounds with 
differential abilities to undergo single-electron or two-electron reactions, creating a spectrum 
of interaction types and degrees of reactivity with TrxR1 140. For example, juglone, a quinone 
found in walnuts, is known to act as a substrate of TrxR1 and is also an inhibitor of TrxR1 
204,205. This dual activity of juglone occurs because of the two unique reactive sites within 
TrxR1. Juglone appears to inhibit the selenol-thiol motif located at the C-terminus of the 
enzyme, while acting as a substrate to the dithiol motif located at the N-terminus of the 
enzyme 135. Some quinone and other naturally occurring compounds, as seen with some of the 
transition metal-containing TrxR1 inhibitors, are non-specific to TrxR1, and can react with 
and inhibit other cellular enzymes like GR 206.   
There are a series of compounds that are used to treat various human diseases and ailments 
also known to inhibit TrxR1 activity. In addition to the compounds currently utilized for 
therapy, there are compounds with TrxR1 inhibitory activity being tested for potential future 
health-based purposes. This group of compounds is comprised of, but not limited to: 
selenium and tellurium containing compounds 207-209, arsenicals 210-212, benzene derivatives 
205,213,214, 13-cis-retinoic acid 215, busulfan 153, PRIMA 216, RITA 217, PX-12 218, iodoacetic acid 
214, and 4-vinylpryidine 214. Some synthetic compounds and drug metabolites understood to be 
extremely toxic to humans can also inhibit TrxR1, e.g. acrolein 219 and metabolites of 
acetaminophen (NAPQI)220,221.  
The research examining TrxR1 inhibitors described here shows how diverse an inhibitor of 
the enzyme can be. The sources of TrxR1 inhibitor research also show that the majority of 
TrxR1 inhibitor research is geared toward anticancer therapy.  Some of the transition-metal 
based inhibitors and organic small molecules of TrxR1 are highly toxic carcinogens; and 
therefore convey a message, that just because a small molecule is an inhibitor of TrxR1 it is 
not necessarily beneficial for human health or may serve therapeutic benefit.   
  
1.5 THIOREDOXIN REDUCTASE 1 IN CANCER 
The implication of TrxR1 as an integral component of cancer cell growth and survival was 
first directly proposed in the year 2000 116,222,223. Being that TrxR1 has a wide variety of 
substrates (as described above), its potential effect toward supporting cancer cells occurs in 
many different ways. TrxR1 is known to directly react with ROS, serving as an immediate 
antioxidant in addition to its reductive support to other antioxidants in the Trx pathway 144. Of 
important note, TrxR1’s direct antioxidant activity is Sec dependent 134. Indirectly, there are 
oncogenic signaling and regulatory mechanisms in cancer cells positively correlating to 
TrxR1 activity. Experimental research has discovered multitudes of TrxR1 inhibitors (as 
described above) and has connected therapeutic efficacy to inhibition of the enzyme. The 
summation of these observations fuels the notion of the enzyme being a potential anticancer 
drug target 59,212,224-228.  
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As previously utilized by Elias Arnér and Arne Holmgren 59, the original six hallmarks of 
cancer will here serve as a rough template to describe the indirect roles of TrxR1 in cancer 
(Fig.7). Additionally, this section will examine TrxR1 as a non-oncogenic addiction 17 and 
describe a functional switch of the enzyme from an antioxidant to a prooxidant through 
certain small molecule inhibition.  
 
Figure 7.  Thioredoxin Reductase 1 Hallmarks of Cancer. TrxR1 activity, expression, and inhibition are 
associated with five capabilities of cancer cells defined in Hanahan and Weinberg’s original six hallmarks of 
cancer. External boxes depict the genes and proteins that connect TrxR1 to each hallmark.  Evidence of TrxR1 
linked to oncogenic factors includes: ERBB2 and TXNRD1 expression correlate to worsened prognosis and 
survival; TrxR1 activation and suppression positively correlates to hTERT activation and suppression; Hgf and 
Opn1 expression levels correlate to TrxR1 expression and worsened prognosis; HIF-1 and VEGF expression and 
activity, as well as suppression, correlates to TrxR1 activities; ASK1 inhibition through TrxR1-redcued Trx1. 
Experimental evidence is lacking for a connection of TrxR1 expression and activity in cancer cells or tumor 
models to evasion of growth suppressors.  
1.5.1 Expression Levels and Prognosis 
Overexpression of TrxR1 within human tumor tissues is both difficult to access and highly 
variant between different tumors of the same tissue type or status grade 229. Within specific 
cancers, like colorectal cancer for instance, tumors have been shown to have a broad 
spectrum of TrxR1 levels 230. Berggren et. al 1996 showed there to be twice as much TrxR1 
activity in colon tumor tissue samples compared to normal tissue, while the same samples 
displayed a wide, 23-fold range in TrxR1 mRNA levels 230. Despite this variance in individual 
tumors, and differential results between diagnostic methods, TrxR1 expression and activity 
levels have been repeatedly observed to be upregulated in tumors as a whole. Increases in 
TrxR1 expression levels in human tumor samples have been shown in multiple independent 
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studies, including mammary carcinomas 231, advanced malignant melanomas 232, thyroid 
cancers 233, tongue squamous cell carcinoma 234, and non-small cell lung carcinoma 235. 
Furthermore, the high expression and activity levels of TrxR1 noted in many carcinomas 
have repeatedly correlated to worsened prognosis and a decreased 5-year survival 107,236,237.   
 
1.5.2 Enabling Sustained Proliferation and Replicative Immortality 
Cancer cells have a high replicative drive, and therefore have a large demand for DNA 
synthesis.  In order to make DNA, ribonucleotides must be reduced to deoxyriobonucleotides 
by the redox dependent enzyme RNR 238. RNR activity is dependent upon its reduction, 
facilitated through the thioredoxin pathway, and therefore implies TrxR1 overexpression to 
increase the capacity for RNR activities 239,240. Another example of TrxR1-associated 
sustained proliferation was observed in three cohorts examining TXNRD1 (gene name for 
TrxR1) and thioredoxin interacting protein (TXNIP) mRNA expression levels. This study 
showed TXNRD1 expression correlated to worsened prognosis and ERBB2 positive tumors 
231. ERBB2, more commonly known as HER2/neu, is overexpressed in some breast cancers 
and is part of the protein family of epidermal growth factor receptors (EGFR) 241. EGFR 
receptors are responsible for a large degree of kinase activity and are associated with 
activation of DNA synthesis and cell proliferation 242.   
An additional DNA-dependent factor in cancer cell growth with connections to TrxR1 is 
human telomerase reserve transcriptase (hTERT) 243. Telomeres, the ends of DNA, become 
shortened after cells replicate and divide 244.  After a series of replications, the telomeres will 
become too short, causing the cells to undergo cell senescence or apoptosis.  hTERT is able 
to add nucleotides to these shortened ends, sustaining the replicative potential in the cell. This 
protein is known to be a driver of replicative immortality in cancer cells 245. Using antisense 
TrxR1 RNA, hTERT levels were able to be effectively decreased in conjunction with reduced 
cancer cell growth 246. 
 
1.5.3  Inducing Angiogenesis 
A major transcriptional regulator of angiogenesis is the hypoxia-inducible factor 1 alpha 
(HIF-1) 247,248. Studies have shown HIF-1 is upregulated in tumors and supports cancer cell 
survival and growth in low oxygen environments 249,250. Increased HIF-1 levels have been 
additionally correlated to an increased expression of the downstream transcription target 
VEGF, a signaling protein directly responsible for angiogenesis and vascularization 251. 
Transient transfection of Trx1, the major substrate of TrxR1, into cells resulted in an 
increased expression of HIF-1 under hypoxic conditions, and also increased intracellular and 
extracellular levels of VEGF 252. 1-methylpropyl 2-imidazolyl disulfide (PX-12), a member of 
the TrxR1 and Trx1 inhibiting 2-imidazolyl disulfide small molecule family, was shown to 
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decrease HIF-1 and VEGF levels in both breast and colon cancer cell lines 218. Trx1 
expression levels also correlated to HIF-1 and VEGF expression in patients with liver cancer 
and negatively correlated to 5-year survival 108. Additional evidence connecting TrxR1 
activity to HIF-1 and VEGF levels has been shown with electrophilic prostaglandins. A series 
of electrophilic prostaglandins both inhibited TrxR1 activities and HIF-1 transcription in a 
cellular context 196.  
 
1.5.4 Inhibition of Apoptosis 
A strong connection between TrxR1 and apoptosis is through Trx1 binding to, and inhibiting 
the activity of ASK1 253. ASK1 is a mitogen-activated protein (Map) kinase, which upon 
activation subsequently activates other map kinases p38 and JNK to initiate apoptosis 254. 
Reduced Trx1 binds to ASK1 preventing autophosphorylation at the threonine 838 residue. 
When a cell is exposed to oxidative stress, for example high levels of H2O2, the reduced 
cysteine residues of Trx1 become oxidized and the protein releases from ASK1 255. A vexing 
observation in cultured tumor cells with regards to ASK1 is that many have been observed to 
produce abnormally high levels of H2O2 256. The prevention of ASK1 dependent induction of 
apoptosis in cells with high levels of H2O2 may actually occur through elevated TrxR1 
performing increased antioxidant activity and sustaining the reduced state of Trx1, leading to 
continual inhibition of ASK1.  
 
1.5.5 Activating Invasion and Metastasis 
With the overexpression of TrxR1 observed in different types of cancers, a group of scientists 
examined the effects of TrxR1 in its ability to affect xenograft establishment in mice 257. Yoo 
et al. 2006 used siRNA technology to knockdown TrxR1 in human lung cancer cells, and 
found inhibition of TrxR1 in these cells significantly reduced their ability to form xenografts 
in mice. Metastases were also found to be less frequent in the mice with xenografted TrxR1 
knockdown cells compared to mock-seq controls. Examining 96 gene products associated 
with malignancy, Yoo et al. 2006 also observed hepatocyte growth factor (Hgf) and 
osteopontin (Opn1) to be decreased in the TrxR1 knockdown cells. Hgf is increased in 
esophageal cancer biopsies and exposure of Hgf to cultured cells can increase VEGF levels 
and p42/44 map kinases 258. Opn1 increased expression has been observed in many different 
human cancers and has been linked to prognosis 259.  
 
1.5.6 Thioredoxin Reductase 1 as a Non-Oncogenic Addiction 
TrxR1 can be considered a non-oncogenic addiction through its supportive role toward cancer 
cell stress phenotypes 17. The major way in which TrxR1 appears to combat cancer cell stress 
Elucidation of Thioredoxin Reductase 1 as an Anticancer Drug Target 
   
 
 21 
is through its antioxidant activities. As Trachootham et al. 2009 describe, cancer cells are able 
to survive increased oxidative stress through activation of antioxidant pathway 109. With the 
observed increased expression in various tumors (as described above), TrxR1 serves as a 
direct and indirect support mechanism to antioxidant activities. Experimental evidence shows 
TrxR1 may additionally serve as functional support to metabolic and DNA stress cancer cell 
phenotypes 17. This is observed through the corollary expression levels of TrxR1 with ERBB2  
231 and hTERT 246 in cancer cells, corroborating TrxR1 activity as a response to, or in 
association with, oncogenic factors.    
 
Figure 8. Catalysis of TrxR1 and SecTRAPs. A) Catalysis and substrate activity of TrxR1.  NADPH donates 
electrons to TrxR1 through the FAD (yellow) moiety.  Electrons subsequently flow to the N-terminal dithiol 
motif of one subunit, then to the C-terminal selenothiol motif of the other subunit.  The reduced C-terminus can 
then reduce cellular substrates like Trx1 (orange). Red arrows depict electron flow. B) Catalyis and substrate 
activity of SecTRAP proteins.  The reduced selenium atom is covalently modified by a small molecule inhibitor 
(blue “X”).  NADPH can still donate electrons to the FAD moiety (yellow) and electrons can flow to the N-
terminal dithiol motif. Electrons cannot flow to the C-terminus in SecTRAP proteins and cannot reduce Trx1 
(orange).  The N-terminus in the SecTRAP remains reactive, resulting in NADPH-oxidase like activity. 
1.5.7 Selenium Compromised Thioredoxin Reductase-Derived Apoptotic Proteins 
A proposed effect of TrxR1 inhibition is the ability of small molecule inhibitors of the 
enzyme being able to form a selenium compromised thioredoxin reductase-derived apoptotic 
protein (SecTRAP)191,260,261. In order for a SecTRAP to be formed, a small molecule inhibitor 
has to bind to the reduced C-terminal redox motif of TrxR1 where the Sec amino acid is 
located. Normally, electrons are received from NADPH and flow within TrxR1 from the 
FAD moiety to the N-terminal dithiol motif of one subunit, and finally to the C-terminal 
selenothiol motif of the other subunit. After reduction of the selenium atom, substrates like 
Trx1 can react with TrxR1 and become reduced (Fig. 8A). When small molecules covalently 
modify the selenium atom and not other parts of the enzyme, the homodimer can still react 
with NADPH and become reduced at the N-terminus. This type of reduced TrxR1 dimer is 
unable to react with Trx1, but it is able to react with other substrates within a purified enzyme 
experimental setting, sustaining NADPH consumption (Fig. 8B) 175. The postulate of 
SecTRAP functionality in a cellular context proposes the inhibited TrxR1 is converted into an 
NADPH oxidase, consuming reducing equivalents within a cell while lacking its typical 
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redox-dependent, antioxidant activity. Therefore, SecTRAPs should have a gain of function 
within cancer cells, transforming TrxR1 from an antioxidant protein to a prooxidant protein. 
This gain of function could result in the loss of TrxR1 antioxidant activity as well as 
increased ROS production, making TrxR1 an anticancer drug target candidate with unique 
modulatory functions.   
‘ 
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2 RATIONALE AND AIMS OF THESIS 
The multitude of small molecules known to inhibit TrxR1 combined with observations of the 
enzyme displaying increased activities within cancer cells have long driven the idea of the 
enzyme being an anticancer drug target. With the highly reactive nature of the compounds 
that interact with TrxR1, it has not been possible to ascertain whether the effects of inhibiting 
the enzyme significantly contribute to anticancer efficacy. The focus of these studies is to 
further examine the potential of TrxR1 as an anticancer drug target through searching for 
novel inhibitors of TrxR1 with the ability to elicit anticancer effects. Additionally, this thesis 
attempts to characterize the potential contribution of TrxR1 inhibition from experimental 
anticancer small molecule drugs known to affect other cellular targets.  Specifically, the focus 
of each has been: 
Paper I 
• Developing a proof of principle quantitative high throughput screen for the discovery 
of novel substrates and inhibitors of TrxR1. 
 
Paper II 
• Examining the cellular uptake and apoptosis-inducing activities of the 19S 
deubiquitinase inhibitor b-AP15.  
• Elucidating the reactive site of b-AP15 compared to a series of analogs. 
• Comparing the effects of b-AP15, its analogs, and the FDA approved proteasome 
inhibitor, bortezomib, as inhibitors of TrxR1. 
• Examining the contribution of TrxR1 inhibition to the induction of apoptosis caused 
by proteasome inhibitors.  
 
Paper III 
• Comparing the biochemical and cellular effects of MJ25 to Auranofin within p53 and 
redox systems, and the  ability of both compounds to inhibit the viability of milignant 
melanoma cell lines.  
 
Paper IV 
• Performing a large high throughput screen to discover novel inhibitors of TrxR1.  
• Modulating TrxR1 inhibitory activities of small molecules, and correlating enzymatic 
inhibition and specificity to effects on cell viability. 
• Examining the potential for novel TrxR1 inhibitors to inhibit cancer cell viability in 
vitro and in vivo. 
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3.1 PAPER I 
Inhibition of thioredoxin reductase 1 by porphyrins and other small molecules identified by a 
high-throughput screening assay 
Stefanie Prast-Nielsen, Thomas S. Dexheimer, Lena Schultz, William C. Stafford, Qing 
Cheng, Jianqiang Xu, Ajit Jadhav, Elias S.J. Arnér, Anton Simeonov. Free Radic Biol Med. 
2011 May 1;50(9):1114-23 
 
Figure 9. Representation of Dual-purpose HTS Assay 262. Substrate activity is determined through the TrxR1-
dependent transfer of electrons of NADPH to test compounds, resulting in a decrease in NADPH levels. 
Inhibitory activity is determined through the addition of the TrxR1 substrate selenite (SeO32-) and a lack of 
NADPH consumption.  NADPH consumption is determined fluorometrically: excitation 340nm, emission 
450nm.  
3.1.1 Assay Design and Validation 
Inhibitory activity of TrxR1 has been widely studied through the utilization of purified 
enzyme and the DTNB assay 263. This assay was originally designed for use in 1ml cuvettes 
and later adapted for use in 96-well format 176. In order to study a wide range of small 
molecules as modulators of TrxR1 activity, this study developed an assay for examining both 
inhibitory and substrate activities of compounds utilizing the fluorescence characteristics of 
NADPH. Utilization of the fluorometric characteristics of NADPH in lieu of a substrate like 
DTNB increased the sensitivity of activity detection, and allowed for functional adaptation 
from 96-well (100µl min volume) to 1536-well (23nl) format.  
Initial validation of the assay utilized the known substrate Juglone and known inhibitor 
Auranofin, each of which displayed robust substrate or inhibitory responses respectively. To 
further validate the potential of the 1536-well format assay, the library of pharmacologically 
active compounds 1280 (LOPAC1280) was screened. Use of the LOPAC1280 library confirmed 
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previously known inhibitors of TrxR1 e.g. cisplatin, myrcetrin, chlorambucil, and melphanin. 
The assay also validated known substrates of TrxR1, like 2,3-dimethoxy-1,4-naphthoquinone 
(DMNQ), although the difference between the substrate compound and control were only 
moderate. The assay additionally discovered novel inhibitors of TrxR1, notably, 
protoporphyrin IX (PpIX).   
 
3.1.2 Protoporphyrin IX 
A more detailed analysis of PpIX in the TrxR1 system showed the heme precursor compound 
did not interact with NADPH. Inhibition of TrxR1 through PpIX was found to be irreversible, 
and the compound was able to competitively inhibit TrxR1 in the presence of Trx1. Analogs 
of PpIX, N-methyl protophorphyrin IX (NMPP) and hemin, inhibited TrxR1 with differential 
inactivation kinetics compared to PpIX. NMPP, with a methyl group situated in the core of 
the porphyrin ring, was a weaker inhibitor of TrxR1 while the iron containing hemin had 
complex inactivation kinetics. PpIX did not display inhibitory activities against the U498C 
mutant of TrxR1, suggesting the compound binds at the main active site of the enzyme. All 
three compounds inhibited cellular TrxR1, though at different potencies. PpIX, being the 
most potent TrxR1 inhibitor of the three compounds, displayed the greatest inhibition of cell 
viability and DNA proliferation.   
This paper established a high-throughput screening ability of TrxR1 and discovered novel 
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3.2 PAPER II 
The 19S Deubiquitinase Inhibitor b-AP15 Is Enriched in Cells and Elicits Rapid 
Commitment to Cell Death 
Xin Wang, William Stafford, Magdalena Mazurkiewicz, Mårten Fryknäs, Slavica Brjnic, 
Xiaonan Zhang, Joachim Gullbo, Rolf Larsson, Elias S. J. Arnér, Padraig D’Arcy, and Stig 
Linder. Mol Pharmacol 2014 Jun;85(6):932-45   
 
Figure 10. Chemical Structure of b-AP15 
3.2.1  Proteasome Inhibition 
b-AP15 is a potent inhibitor of the ubiquitin specific peptidase 14 (USP14) and ubiquitin 
carboxyl-terminal hydrolase L5 (UCHL5) deubiquitinases, which causes functional 
impairment of the 19S subunit of the 26S proteasome and produces anticancer effects in 
multiple mouse models 264. This study here confirmed the previous observations of 
deubiquitinase inhibitory activity using siRNA against both USP14 and UCHL5 enzymes, 
and compared those effects with treatment of b-AP15. Structure activity relationship (SAR) 
analysis of b-AP15 showed the α,β-unsaturated carbonyl, the Michael acceptor group and not 
the acrylamide moiety, is the regulating molecular feature of b-AP15’s inhibitory activity. 
Debate in the literature regarding the reversible nature of deubiquitinase inhibitors prompted 
additional examination of the type of inhibition of b-AP15 265,266. b-AP15 was here confirmed 
to be partially reversible with both cell extracts and in intact cells. 
 
3.2.2 Uptake, Pharmacokinetics, and Metabolism 
Treatment of radiolabeled b-AP15 here showed the compound is rapidly taken up in cells, 
with washout of b-AP15 not effecting proteasome inhibition for up to 8 hours after initial 
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t1/2=3.7, correlating the quick uptake of the compound in cells to the short plasma half-life.  
Additionally, metabolite profiling in both human and mouse hepatocytes showed that 19 and 
17 metabolites of b-AP15 were formed, respectively. Glucoronidation, S-glutathionylation, 
and S-cysteine conjugates were some of those observed. 
 
3.2.3 Oxidative Stress and Thioredoxin Reductase Inhibition 
The observed increases of cellular hemeoxygenase-1 (Hmox-1) levels with b-AP15 treatment 
being greater than the Hmox-1 increases seen with bortezomib treatment prompted further 
investigation about the mechanism in which b-AP15 induces oxidative stress. b-AP15 was 
found to be a potent and irreversible inhibitor of TrxR1 in recombinant enzyme and cellular 
assays, with selectivity towards TrxR1 over GR. Bortezomib, however, did not inhibit TrxR1. 
Co-treatment of Auranofin with Bortezomib failed to evoke the same degree of apoptosis 
compared to b-AP15, showing the effect of b-AP15 on the proteasome and TrxR1 is superior 
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3.3 PAPER III 
Redox effects and cytotoxic profiles of MJ25 and Auranofin towards malignant melanoma 
cells 
Marijke C.C. Sachweh*, William C. Stafford*, Catherine J. Drummond, Anna R. McCarty, 
Maureen Higgins, Johanna Campbell, Bertha Brodin, Elias S.J. Arnér and Sonia Lain. 
Oncotarget 2015 May 12;(6): 16488-16506 
*These authors have contributed equally to this work. 
 
Figure 11. Chemical Structures of MJ25 and Auranofin. 
3.3.1 p53 Activation in Normal and Cancer Cell Lines 
Utilizing a forward chemical genetics approach, a compound named 2-{[2-(1,3-benzothiazol-
2-ylsulfonyl)ethyl]thio}1,3-benzoxazole (MJ25) was found to reactivate p53 transcription in 
melanoma cells.  This compound was additionally found to inhibit TrxR1 in a separate high-
throughput screen. The combination of these findings supported further inquisition as to 
MJ25’s efficacy in melanoma cells, as well as inquiry into the role TrxR1 may serve in this 
specific type of cancer. Auranofin, a gold compound and TrxR1 inhibitor, was incorporated 
into these studies as a positive control, redox-modulating compound.  
p53 characterization of MJ25 in cellular models showed that the compound could activate 
p21 expression in normal human fibroblast (NHDF) cells with mutant or null p53, without 
affecting p53 expression levels. Cancer cells, alternatively, did not show any change in p21 
levels, but displayed an increase in p53 expression levels. Auranofin showed similar effects 
on p21 and p53 expression levels between normal and carcinogenic cell lines. However, the 
original p53-transcriptional luciferase that showed MJ25 to be a slight inducer of p53 
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transcriptional activation of p53 between the two compounds was observed both in the 
presence and absence of nutlin-3. 
 
3.3.2 MJ25 and Auranofin Potency in Cell Culture 
MJ25 and Auranofin displayed potency in multiple melanoma and colon carcinoma cell lines, 
including cell lines deficient in p53 expression and possessing the BRAFV600E mutation. MJ25 
and Auranofin showed differential effects towards NHDFs, where MJ25 completely lacked 
toxicity and Auranofin inhibited colony formation.  
 
3.3.3  MJ25 and Auranofin in Redox Systems 
TrxR1 activity assays showed that Auranofin inhibits TrxR1 in low nanomolar concentrations 
and MJ25 inhibits TrxR1 in low micromolar concentrations. Examining their mode of 
binding, MJ25 and Auranofin were found to be irreversible inhibitors of TrxR1. Using doses 
to completely inhibit the C-terminal active site of TrxR1, MJ25 and Auranofin inhibition still 
allowed for a high degree of N-terminal active site function. This sustained activity of TrxR1 
in the presence of both compounds suggests both compounds cause SecTRAP formation. 
Unlike MJ25, Auranofin displayed inhibitory activities towards GR at higher concentrations.   
MJ25 and Auranofin displayed a rapid inhibition of TrxR1 in cell culture, and such inhibition 
of activity slowly recovered back to vehicle controls after 24 hours. This observed inhibition 
and eventual recovery of cellular TrxR1 activity after treatment of the compounds correlated 
to Nrf2 expression. The Nrf2/TrxR1 correlation was inverted, providing evidence of TrxR1 
inhibition inducing an Nrf2 response. Auranofin treatment induced a potent increase of 
Hmox-1 expression after 6 hours, while MJ25 did not cause a significant induction of Hmox-
1 levels. Both compounds were more potent in the SRB assay when cells were pretreated 
with BSO, again with Auranofin having a larger increase in potency. High concentrations of 
MJ25 and Auranofin also caused an increase in ROS production, as observed with DCF 
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3.4 PAPER IV 
Drug Mediated Inhibition of Thioredoxin Reductase 1 is Sufficient for Anticancer Efficacy 
William C. Stafford, Xiaoxiao Peng, Maria Hägg Olofsson, Xiaonan Zhang, Diane Luci, Li 
Lu, Qing Cheng, Thomas S Dexheimer, Lionel Tresaugues, Daniel Martinez Molina, Nathan 
Coussens, Martin Augsten, Hanna-Stina Martinsson Ahlzén, Pär Nordlund, Arne Östman, 
Sharon Stone-Elander, David Maloney, Ajit Jadhav, Anton Simeonov, Stig Linder and Elias 
SJ Arner. Manuscript 
 
Figure 12. µPET imaging of tumor xenografts in mice treated with TRi-1. A) Full body µPET image of a 
mouse injected with [2-18F]-2-fluoro-2-deoxy-D-glucose ([18F]-FDG). White arrows indicate xenograft tumor 
cells (t), brain (br), kidneys (k), and bladder (bl). Colors represent a heat map with short (blue) to long 
(red/white) colors correlating to low and high [18F]-FDG uptake respectively. B) [18F]-FDG uptake in a 
xenograft tumor after three days of treatment with vehicle control. C) [18F]-FDG uptake of a xenograft tumor 
after three days of treatment with 5mg/kg TRi-1, with a pronounced non-metabolic core.  
3.4.1 Novel Inhibitor Selection and Target Validation 
A large quantitative high-throughput screen was performed with 386,658 compounds in order 
to discover novel inhibitors of TrxR1.  3,977 compounds displayed potency and 53 
compounds were selected for further analysis.  Performing a competitive TrxR1 inhibitory 
assay, a GR assay, and cell viability assay in esophageal carcinoma cells, two structurally 
diverse compounds were selected as lead candidate compounds.  These compounds were 
named Thioredoxin Reductase inhibitors 1 and 2 (TRi-1, TRi-2). TRi-1 and TRi-2 inhibited 
TrxR1 activity in enzymatic and cellular models, and lacked inhibitory activity toward GR.  
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Generation of a series of analogs of TRi-1 and TRi-2 allowed for performing SAR.  A simple 
modification of each compound rendered them inactive as TrxR1 inhibitors.  These inactive 
TrxR1 inhibitors did not inhibit cancer cell viability in culture.  For TRi-1, a modification of 
the compound abolished its specificity, making it an effective GR inhibitor.  This compound 
displayed an increased potency in cells, inhibiting cell viability to a greater extent than its 
parental and more specific compound.  
 
3.4.2 SecTRAP Formation and Induction of Cellular Oxidative Stress 
TrxR1, treated with concentrations of TRi-1 or TRi-2 aimed to fully inhibit the C-terminus of 
the enzyme displayed differential N-terminus redox activities. This suggested that TRi-1, but 
not TRi-2, interacts with TrxR1 like Auranofin does, forming SecTRAPs.  TRi-1, TRi-2, and 
Auranonfin were individually treated on cells and examined in an Amplex Red assay to 
determine H2O2 levels after treatment.  TRi-1 and Auranofin both induced H2O2 levels in a 
time and concentration dependent fashion, whereas TRi-2 did not.  Validating the H2O2 
generated from TRi-1 treatment comes from TrxR1 modification into a SecTRAP, a 
mitochondrial respiration assay was performed.  This assay showed TRi-1 does not affect 
mitochondrial function, although Auranofin was shown to block basal and maximal 
mitochondrial respiration after short or long exposure times.     
 
3.4.3 TRi-1 versus Auranofin 
Side-by-side comparisons of TRi-1 and Auranofin in cell viability assays showed both 
compounds effectively inhibit cell viability in a wide range of cancer cell lines, though 
Auranofin was more potent than TRi-1.  The increased potency of Auranofin compared to 
TRi-1 was also observed in a clonogenic assay. Testing thermal stability of TrxR1 upon 
treatment of TRi-1 or Auranofin, TRi-1 was found to stabilize the enzyme back toward the 
more temperature resilient oxidized state.  Auranofin did not display thermal stabilization of 
TrxR1.  Examining the effect of GSH on each compound’s ability to inhibit TrxR1, 
Auranofin could not efficiently inhibit TrxR1 in the presence of NADPH, Trx1, and 
increasing concentrations of GSH. TRi-1 inhibitory activity of TrxR1, alternatively, was not 
affected by the presence of GSH.    
 
3.4.4 Mouse Studies 
Repeated dose toxicity studies of TRi-1 and Auranofin showed both compounds to be well 
tolerated over a five-day treatment regimen.  Mice in the repeated dose toxicity study bore 
FaDu cell carcinoma xenografts, and both compounds effectively reduced tumor cell growth 
compared to vehicle control.  Small animal positron emission tomography (µPET) studies 
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examining metabolic changes of xenografts after treatment with TRi-1 showed tumors 
decreased in total metabolic activity compared to controls.  PET images also revealed that the 
mice treated with TRi-1 displayed stark non-metabolic cores in the center of the xenografts.  
Finally, PyMT-MMTV syngenic mice treated with either TRi-1 or Auranofin over a low 
dose, long treatment period displayed a significant decrease in mammary tumor growth 


























The results of these studies provide further evidence for the relevance of TrxR1 as an 
anticancer drug target.  These studies bring up questions and insights toward what types of 
compounds can be efficient TrxR1 inhibitors, as well as describe different ways in which 
early drug discovery can occur. Within each paper included in this thesis new inhibitors of 
TrxR1 were discovered, though how useful each new inhibitor might be as an anticancer drug 
is not overtly clear.  The information these different studies provide about TrxR1 inhibition 
and the promise of these newly found TrxR1 inhibitors as anticancer drug candidates will be 
discussed on an individual basis.   
 
3.5.1 Paper I 
The development of a high-throughput screen (HTS) for TrxR1 substrates and inhibitors 
provided a great opportunity to take a broad look into the realm of molecules that interact 
with the enzyme.  The vast amount of research performed on TrxR1 inhibitors and substrates 
has occurred over decades, utilizing various experimental parameters and focusing on small 
numbers of compounds at a time.  Developing an assay with high-throughput capacity 
allowed for compounds to be tested against TrxR1 in a uniform fashion making comparisons 
between compounds quick and efficient.  Utilization of the LOPAC1280 served as a an 
excellent initial set of compounds to verify the assay because of its large, yet manageable 
size, and for the library containing compounds that have been previously found to be TrxR1 
substrates or inhibitors. 
The porphyrins discovered in this study were effective inhibitors of TrxR1 and inhibited cell 
viability in carcinoma cancer cells lines, suggesting them to be interesting anticancer drug 
candidates.  A look into the history of porphyrins as drugs suggests an alternative perspective, 
however.  Previous attempts to develop prophyrin-based compounds as anticancer drugs have 
been made, though were met with mixed success.  Motexafin gadolinium, a more complex 
porphyrin compound, was discovered to be an inhibitor of TrxR1 and RNR, displaying 
potential to serve as an anticancer therapeutic 267.  Motexafin went very far within the pipeline 
of drug development and was tested in a Phase III clinical trial, but failed to show significant 
improvement in therapy compared the controls 268,269.  Interesting characteristics of 
porphyrins do exist, like their reported increased uptake in tumor cells versus normal cells 270 
and photodynamic characteristics 271, providing other potential venues for porphyins to serve 
therapeutic benefit. Nevertheless, the low solubility and high propensity for aggregation of 
porphyrins make them difficult drugs to work with, demanding a great deal of optimization 
that may simply lead back to Motexafin, making the pursuit of developing porphyrins as 
anticancer therapeutic drugs a difficult and questionable task.     
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3.5.2 Paper II 
This analysis of b-AP15 led to insights of the drug’s active moiety and intrigue into its 
mechanism(s) of action within the cell.   Testing a series of b-AP15 analogs in cell viability 
resulted in the understanding of the active site in b-AP15, the Michael acceptor moiety.  
Performing SAR analysis, even with small batches of analogs as done in this study, can 
provide large amounts of insight into a compound’s functionality.  The information gained 
can lead to an intelligent design of future analogs with functional modifications that might 
improve on subsequent drug development hurdles like absorption, distribution, metabolism, 
excretion, and toxicity (ADMET) properties without directly affecting the drug’s potency.  
Understandably, any modification to a compound can alter its efficacy in an unexpected 
fashion, though this type of experimental mentality can drive a “what not to do” awareness, 
saving both time and resources in the future. 
The combination of multiple types of cellular and enzymatic assays in this study not only 
helps for future analog development of b-AP15, it provides a look into how specific 
components of the cell may or may not be connected in function. Examination of 
deubiquitinase, TrxR1, and GR inhibitory activities together with phenotypic responses like 
cell viability and apoptosis showed that auranofin does not inhibit deubiquitinases. It also 
shows the concomitant inhibition of deubiquitinases and TrxR1 through the dual exposure of 
Bortezomib and Auranofin cannot reproduce b-AP15’s effects on apoptosis.  
An analysis embedded within this data brings up interesting conjecture. VLX1545, b-AP15, 
and b-AP107 all inhibit antioxidant enzymes to different degrees in this study. b-AP107 
inhibits TrxR1, but is the least potent of the three.  b-AP15 is a potent inhibitor of 
recombinantly expressed TrxR1 and does not inhibit GR.  VLX1545 is a promiscuous redox 
inhibitor, inhibiting both TrxR1 and GR. Meaning, b-AP107 < b-AP15 < VLX1545 in 
regards to inhibiting antioxidant enzymes.  The effects of these three compounds on redox 
enzymes directly correlate to the relative Hmox-1 expression levels and inversely correlate to 
induction of apoptosis when these compounds are exposed to cells.  Additionally, b-AP15 
and VLX1545 are indistinguishable in terms of viability, suggesting deubiquitnase inhibition 
and redox inhibition have unique modes of inducing cell death.   
These studies and extrapolations convey b-AP15’s mechanism of action is both a complex 
and an interesting topic for further examination.   
 
3.5.3 Paper III 
A unique aspect of this study can be observed from the way the collaboration for this work of 
TrxR1 inhibitors for the treatment of malignant melanoma began.  MJ25 was initially 
discovered to be a mild activator of p53 transcription in a cell-based luciferase assay.  
Researchers in Sonia Lain’s lab found that MJ25 additionally appeared to be a mild inhibitor 
in a large HTS looking for inhibitors of recombinantly expressed TrxR1.  Observing the 
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connection through MJ25 between the two vastly different assays, the two groups teamed up 
to examine the compound in detail.   
The birth of this collaboration brings to light the benefit of combining completely contrasting 
approaches to anticancer drug research.  Starting from a cell based assay for drug screening is 
a process known as forward chemical genetics.  Forward chemical genetics employs looking 
for a phenotypic response with a compound, then exploring for the targets the compound 
interacts with to induce such a response.  The opposite of forward chemical genetics is 
reverse chemical genetics. Reverse chemical genetics is the process of starting with a specific 
target, proposed to be mechanistically therapeutic upon modulation, and examining the effect 
of a drug’s modulation of such a target toward a phenotypic response. The coalescence of 
these two schools of thought toward anticancer drug development led to the discovery of a 
novel TrxR1 inhibitor, MJ25, and broadened the potential of Auranofin as an anticancer 
therapeutic to malignant melanomas.  
 
3.5.4 Paper IV 
The majority of TrxR1 inhibitor research has focused on a specific compound or a series of 
compounds within a class of molecules on an individual basis. This study took the approach 
of examining as many different compounds as possible in a single experimental setting, and 
from the new inhibitors discovered, examine their potential as anticancer drugs.  
The TrxR1 HTS of 386,658 compounds found 3,977 inhibitors of TrxR1, resulting in a 
1.03% positive hit rate. The percent hit rate showed that the assay is robust, yet specific. In 
order to obtain lead candidate compounds, additional experimentation with more stringent 
parameters had to be performed. Using a Trx1 competitive TrxR1 activity assay required 
TrxR1 inhibitors to be able to inhibit an active redox cycling TrxR1 in the presence of its 
main endogenous substrate. Also incorporating a GR activity assay allowed for selection of 
compounds that would be less likely to inhibit the GSH pathway. The GR assay was critical 
for compound selection in order to effectively test TrxR1 inhibition and not general inhibition 
of redox cycling antioxidant pathways. Lastly testing for inhibition of cancer cell viability 
confirmed that the compounds would have basic anticancer properties.  
Looking on the mechanistic side of TrxR1 inhibition, the two lead compounds TRi-1 and 
TRi-2 showed differential inhibitory qualities toward the enzyme.  Both compounds were 
irreversible, but TRi-1 displayed SecTRAP forming capabilities while TRi-2 did not. Of note, 
Auranofin additionally displayed SecTRAP forming capabilities.  This potential NADPH 
oxidase activity observed with recombinantly expressed and purified enzyme had not yet 
been connected to NADPH oxidase activity in cells. Examining the prooxidant potential three 
compounds in cell culture, TRi-1 and Auranofin both induced H2O2 levels in a time and 
concentration dependent manner. TRi-2 did not affect H2O2 levels.  Since Auranofin is 
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known to interact with the mitochondria, mitochondrial respiration was examined with TRi-1 
and Auranofin.  TRi-1 did not affect mitochondrial respiration while Auranofin was a potent 
inhibitor.  These findings further promote SecTRAP forming capabilities with small molecule 
inhibitors of TrxR1, with resultant effect being increased H2O2 generation. With TRi-2 still 
being an effective inhibitor of cell viability without causing SecTRAP formation, it will be of 
interest to explore the intricate differential inhibition of TrxR1 in cellular settings and how 
different types of TrxR1 inhibition lead to inhibition of cell viability. 
Synthesizing analogs of the lead compounds allowed for another type of validation of 
compound specificity.  From lead compounds TRi-1 and TR-2, analogs that did not inhibit 
TrxR1 were ineffective inhibitors of cell viability.  Conversely, an analog of TRi-1 that 
inhibited both TrxR1 and GR was a more potent inhibitor of cell viability.  This showed that 
there is an ability to modulate inhibitor specificity between similar antioxidant enzymes and 
that specificity, or lack there of, correlates to inhibition of cancer cell viability.   
Harris et al. 2015 have recently argued that inhibition of both pathways can result in 
anticancer efficacy 99. This can be a dangerous and difficult approach to antioxidant pathway 
modulation for cancer therapy.  Normal cells are able to survive off of depletion of either the 
GSH or Trx pathways, but complete inhibition of both pathways can be toxic 272.  
Additionally, studies that look at concomitant inhibition of the GSH and Trx pathway 
typically use doses that will only partially suppress each pathway 273 274. Robust inhibition of 
one of the two pathways can be equally as effective, and with targeting TrxR1 this can be 
achieved with specific inhibitors like TRi-1. The approach of targeting only TrxR1 proved 
effective in multiple mouse models within this study, with TRi-1 significantly inhibiting 
tumor growth or metabolism in all mouse tumor models tested. Corroborating the risk of 
inhibiting both antioxidant pathways, inhibition of both the GSH and Trx pathways in the 
syngenic mouse model experiments of this study was lethal. Control mice were injected with 
BSO or Auranofin with no observed side effects; however, treating the mice with both 
compounds, spaced hours apart, was lethal after the first round of treatments.  
The efficacy of TRi-1 in mouse models shows that a reverse chemical genetics approach 
using TrxR1 as the target is a valid anticancer drug development strategy.  
3.5.5 Conclusions 
The compounds studied within this thesis cumulatively argue the significance of TrxR1 as an 
anticancer drug target. These compounds additionally evidentiate the systematic study of 
covalently modifying small molecule inhibitors sustains a high relevance in drug research and 
development. Covalent modifiers have a rich chemistry and dynamic potential of 
electrophilicity. As seen with the molecules in Papers I, II and IV, the attenuation of 
reactivity is readily possible through modest molecular modifications.  Better understanding 
how to utilize the full electrophilic spectrum of covalently modifying molecules can greatly 
contribute to our grasps on molecular pharmacodynamics and drug potential.   
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In multiple arms of these studies Auranofin was used as a positive control for TrxR1 
inhibition. Within enzymatic, cellular, and xenograft mouse model settings, Auranofin is a 
highly promising drug candidate for anticancer therapy.  It is a potent inhibitor of TrxR1, it 
has fantastic solubility, and it is highly efficacious in in vivo models.  Additionally, Auranofin 
is already FDA approved, allowing it to have quickly transcended into multiple clinical trials. 
Although Auranofin is described as a TrxR1 inhibitor, the small molecule has other noted 
activities and reactivity. Auranofin inhibited GR at high doses in Paper III and dramatically 
impaired mitochondrial respiration in Paper IV.  These observations suggest a lack of 
specificity that may induce toxicity.  It will be of great interest to understand the tolerance 
and efficacy of Auranofin in treating cancer patients.  
Oxidative stress and antioxidant redox pathways are clearly cellular dynamics and pathways 
exploited in cancer. Even though manipulating oxidative stress is an effective method for 
cancer treatment, methods to improve therapeutic efficacy and reduce unwanted toxicities 
may be developed through continuing to increase our knowledge of the cellular mechanisms 
involved in redox biology. The complexity of cancer cells makes them elusive, enigmatic 
aberrations of the human body. The entanglement and sensitivity of antioxidant redox 
pathways makes its study abstruse and obscure.  Continuing to research and understand how 
the endogenous antioxidant redox pathways support cancer survival or how they can be 
manipulated for cancer therapy will only prove to expand upon the successful treatment of 
cancer. 
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